Jump to page content
Ignyta, Nerviano sign license deal for two first-in-class kinase inhibitors
Ignyta (RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, an oncology discovery organization, have signed a license agreement that grants Ignyta exclusive global development and commercialization rights to two new drug development programs, which Ignyta will refer to as RXDX-103 and RXDX-104.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests
Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc"
The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Buy online from $250